Trials / Terminated
TerminatedNCT00113971
Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)
A Randomized Phase II Pharmacokinetics/Pharmacodynamics Study of Epratuzumab in Patients With Systemic Lupus Erythematosus
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (planned)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to evaluate how epratuzumab is processed by the body (pharmacokinetics) and whether 2 dose levels of epratuzumab are safe and effective in patients with SLE.
Detailed description
This study is planned to provide information on how the body processes epratuzumab and how epratuzumab affects the body when epratuzumab is given once weekly for 4 weeks in a row at one of 2 different dose levels. Additional information will be obtained related to the natural variability of disease activity in SLE patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | epratuzumab |
Timeline
- Start date
- 2005-04-01
- Primary completion
- 2007-03-01
- Completion
- 2007-06-01
- First posted
- 2005-06-13
- Last updated
- 2012-04-03
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00113971. Inclusion in this directory is not an endorsement.